Table 1.
Demographics and baseline disease characteristics
| Total (N = 57) | |
|---|---|
| Age, n (%) | |
| < 65 | 46 (81) |
| ≥ 65 | 11 (19) |
| Mean (SD) | 55 (9) |
| Median (range) | 54 (27 to 72) |
| Sex, n (%) | |
| Male | 34 (60) |
| Female | 23 (40) |
| ECOG performance status, n (%) | |
| 0 | 21 (37) |
| 1 | 27 (47) |
| 2 | 9 (16) |
| ISS stage, n (%) | |
| I | 15 (26) |
| II | 14 (25) |
| III | 21 (37) |
| Unknown | 7 (12) |
| Type of myelomaa, n (%) | |
| IgG | 25 (44) |
| IgA | 15 (26) |
| Light chain | 17 (30) |
| Kappa | 7 (12) |
| Lambda | 10 (18) |
| Time from initial MM diagnosis, years | |
| Mean (SD) | 4 (2) |
| Median (range) | 4 (1 to 9) |
| Number of prior lines of therapy, n | |
| Mean (SD) | 3 (2) |
| Median (range) | 3 (1 to 9) |
| Autologous stem cell transplantation, n (%) | 10 (18) |
| Prior therapies, n (%) | |
| Proteasome inhibitors | 39 (68) |
| Bortezomib | 39 (68) |
| Carfilzomib | 1 (2) |
| Immunomodulatory agents | 49 (86) |
| Lenalidomide | 25 (44) |
| Pomalidomide | 2 (4) |
| Thalidomide | 39 (68) |
| Proteasome inhibitors + immunomodulatory agents | 34 (60) |
ECOG Eastern Cooperative Oncology Group, IgA immunoglobulin A, IgG immunoglobulin G, ISS International Staging System, SD standard deviation
aThe type of myeloma was assessed per International Myeloma Working Group criteria for diagnosis of multiple myeloma [23]